BioLife Solutions, Inc. (NASDAQ:BLFS) Receives $31.29 Average Price Target from Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received an average rating of “Buy” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $31.2857.

Several equities analysts have recently weighed in on BLFS shares. Stephens started coverage on shares of BioLife Solutions in a research note on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 price target for the company. Zacks Research upgraded BioLife Solutions to a “strong-buy” rating in a research note on Monday, August 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price objective (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th.

BioLife Solutions Stock Performance

Shares of BLFS opened at $26.13 on Thursday. BioLife Solutions has a twelve month low of $19.10 and a twelve month high of $29.55. The firm’s 50 day moving average price is $24.40 and its two-hundred day moving average price is $23.30. The firm has a market cap of $1.25 billion, a P/E ratio of -217.73 and a beta of 1.95.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.31). The business had revenue of $25.42 million for the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%. BioLife Solutions has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that BioLife Solutions will post -0.3 earnings per share for the current fiscal year.

Insider Transactions at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of BioLife Solutions stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $24.40, for a total transaction of $12,200,000.00. Following the completion of the transaction, the insider directly owned 6,707,165 shares in the company, valued at approximately $163,654,826. The trade was a 6.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO Todd Berard sold 10,000 shares of BioLife Solutions stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $25.53, for a total value of $255,300.00. Following the transaction, the chief marketing officer owned 124,618 shares of the company’s stock, valued at $3,181,497.54. This represents a 7.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,019,198 shares of company stock worth $23,981,317. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioLife Solutions

A number of large investors have recently made changes to their positions in BLFS. State of Wyoming increased its stake in shares of BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 1,490 shares during the period. US Bancorp DE increased its stake in shares of BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 1,528 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of BioLife Solutions by 12.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 441 shares during the period. GAMMA Investing LLC increased its stake in shares of BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock worth $96,000 after purchasing an additional 663 shares during the period. Finally, AlphaQuest LLC bought a new position in shares of BioLife Solutions during the second quarter worth approximately $149,000. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.